Tranexamic acid integrated into platelet-rich fibrin produces a robust and resilient antihemorrhagic biological agent: a human cohort study.

Asher, Ran; Oren, Ferdman; Meir, Tamari; Shapira, Lior; Assad, Rawi; Polak, David

Asher, Ran; Oren, Ferdman; Meir, Tamari; Shapira, Lior; Assad, Rawi; Polak, David.

Afiliación

Asher R; Department of Periodontology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Oren F; Department of Periodontology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Meir T; Department of Periodontology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Shapira L; Department of Periodontology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Assad R; Department of Periodontology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Polak D; Department of Periodontology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Electronic address: polak@mail.huji.ac.il.

Oral Surg Oral Med Oral Pathol Oral Radiol ; 134(4): 449-456, 2022 10.

Article en En | MEDLINE | ID: mdl-35718721

Asunto(s)

Antifibrinolíticos; Hemostáticos; Fibrina Rica en Plaquetas; Ácido Tranexámico; Antifibrinolíticos/metabolismo; Antifibrinolíticos/farmacología; Factores Biológicos/metabolismo; Plaquetas; Centrifugación; Estudios de Cohortes; Femenino; Fibrina/metabolismo; Humanos; Masculino; Fibrina Rica en Plaquetas/metabolismo; Ácido Tranexámico/metabolismo; Ácido Tranexámico/farmacología

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ácido Tranexámico / Hemostáticos / Fibrina Rica en Plaquetas / Antifibrinolíticos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Oral Surg Oral Med Oral Pathol Oral Radiol Año: 2022 Tipo del documento: Article País de afiliación: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google